HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines.
Caterina P MinnitiSeda S ToluKai WangZi YanKarl RobertShouping ZhangAndrew S CrouchJoan UehlingerDeepa ManwaniEric E BouhassiraPublished in: Cells (2020)
The concentration of circulating hematopoietic stem and progenitor cells has not been studied longitudinally. Here, we report that the proportions of Lin-CD34+38- hematopoietic multipotent cells (HMCs) and of Lin-CD34+CD38+ hematopoietic progenitors cells (HPCs) are highly variable between individuals but stable over long periods of time, in both healthy individuals and sickle cell disease (SCD) patients. This suggests that these proportions are regulated by genetic polymorphisms or by epigenetic mechanisms. We also report that in SCD patients treated with hydroxyurea, the proportions of circulating HMCs and HPCs show a strong positive and negative correlation with fetal hemoglobin (HbF) levels, respectively. Titration of 65 cytokines revealed that the plasma concentration of chemokines CCL2, CCL11, CCL17, CCL24, CCL27, and PDGF-BB were highly correlated with the proportion of HMCs and HPCs and that a subset of these cytokines were also correlated with HbF levels. A linear model based on four of these chemokines could explain 80% of the variability in the proportion of circulating HMCs between individuals. The proportion of circulating HMCs and HPCs and the concentration of these chemokines might therefore become useful biomarkers for HbF response to HU in SCD patients. Such markers might become increasingly clinically relevant, as alternative treatment modalities for SCD are becoming available.
Keyphrases
- sickle cell disease
- end stage renal disease
- ejection fraction
- liver injury
- liver fibrosis
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- bone marrow
- cell cycle arrest
- gene expression
- drug induced
- cell death
- single cell
- patient reported outcomes
- cell proliferation
- signaling pathway
- patient reported